Journal: CNS Neuroscience & Therapeutics

Article Title: Acetyl‐11‐keto‐beta‐boswellic acid modulates macrophage polarization and Schwann cell migration to accelerate spinal cord injury repair in rats

doi: 10.1111/cns.14642

Figure Lengend Snippet: Information of primary antibodies.

Article Snippet: NRF2 , 1:1000 , Rabbit , bs‐1074R , AB_10855421 , Bioss (Beijing, China).

Techniques: Concentration Assay

Journal: Biomedicines

Article Title: Cadmium-Induced Kidney Injury in Mice Is Counteracted by a Flavonoid-Rich Extract of Bergamot Juice, Alone or in Association with Curcumin and Resveratrol, via the Enhancement of Different Defense Mechanisms

doi: 10.3390/biomedicines9121797

Figure Lengend Snippet: Oligonucleotide primers used for the quantitative Real-time PCR analyses.

Article Snippet: Primary antibodies IL-1β (1:250, Santa Cruz Biotechnology, Dallas, TX, USA) and Nrf2 (1:150, St. John’s Laboratory, London, UK) were incubated overnight at 4 °C in a moisturized chamber.

Techniques: Real-time Polymerase Chain Reaction, Sequencing

Journal: Biomedicines

Article Title: Cadmium-Induced Kidney Injury in Mice Is Counteracted by a Flavonoid-Rich Extract of Bergamot Juice, Alone or in Association with Curcumin and Resveratrol, via the Enhancement of Different Defense Mechanisms

doi: 10.3390/biomedicines9121797

Figure Lengend Snippet: Real-time PCR analysis of Nrf2 ( A ), Nqo1 ( B ) and Hmox1 ( C ). *** p < 0.001 vs. control mice; §§§ p < 0.001 vs. CdCl 2 -treated mice.

Article Snippet: Primary antibodies IL-1β (1:250, Santa Cruz Biotechnology, Dallas, TX, USA) and Nrf2 (1:150, St. John’s Laboratory, London, UK) were incubated overnight at 4 °C in a moisturized chamber.

Techniques: Real-time Polymerase Chain Reaction, Control

Journal: Biomedicines

Article Title: Cadmium-Induced Kidney Injury in Mice Is Counteracted by a Flavonoid-Rich Extract of Bergamot Juice, Alone or in Association with Curcumin and Resveratrol, via the Enhancement of Different Defense Mechanisms

doi: 10.3390/biomedicines9121797

Figure Lengend Snippet: Immunohistochemical localization of Nrf2 in the kidneys. ( A ) In all control groups, Nrf2 immunoreactivity is particularly strong in the tubular wall (arrow). ( B ) In CdCl 2 plus vehicle-treated mice, no Nrf2 immunoreactivity is present. ( C – E ) In mice treated with CdCl 2 plus both doses of Cur and with CdCl 2 plus Re, Nrf2 shows a moderate positivity in some tubules (arrow). ( F ) In mice challenged with CdCl 2 plus BJe at the lower dose, Nrf2 immunoreactivity was lower (arrow) when compared to Cur and Re. ( G – I ) Mice treated with CdCl 2 plus BJe at 40 mg/kg and with CdCl 2 plus both associations: Nrf2 immunoreactivity is high (arrow), similar to controls. ( J ) Morphometric results for Nrf2 expression. Data are expressed in optical units/unit area (OU/UA) (from 0 = black to 255 = white). * p < 0.05 vs. control; § p < 0.05 vs. CdCl 2 plus vehicle. Scale bar: 50 µm.

Article Snippet: Primary antibodies IL-1β (1:250, Santa Cruz Biotechnology, Dallas, TX, USA) and Nrf2 (1:150, St. John’s Laboratory, London, UK) were incubated overnight at 4 °C in a moisturized chamber.

Techniques: Immunohistochemical staining, Control, Expressing

Journal: Neural Regeneration Research

Article Title: Electroacupuncture alleviates cerebral ischemia and reperfusion injury via modulation of the ERK1/2 signaling pathway

doi: 10.4103/1673-5374.187041

Figure Lengend Snippet: Effects of EA on mRNA expression levels of Bax, Bcl-2, GCS and Nrf2 in the ischemic cortex after MCAO. Bax (A), Bcl-2 (B), GCSh (D), GCSl (E) and Nrf2 (F) mRNA expression levels, as assessed by real-time PCR. The Bax/Bcl-2 ratio is shown in C. Data ( n = 7 per group in A–C, n = 5 per group in D–F) are expressed as the mean ± SEM. Statistical significance was determined using analysis of variance followed by Tukey’s multiple comparison test for multiple comparisons. * P < 0.05, ** P < 0.01, vs . sham (sham-operation) group; # P < 0.05, vs . MCAO group; † P < 0.05, vs. EA (MCAO + EA) group. MCAO: Middle cerebral artery occlusion; EA: electroacupuncture; EA plus PD98059: MCAO + EA + PD98059; GCSh: gamma-glutamylcysteine synthetase heavy subunit; GCSl: gamma-glutamylcysteine synthetase light subunit; Nrf2: nuclear factor erythroid 2-related factor 2.

Article Snippet: Then, the sections were incubated with rabbit anti-rat GCS monoclonal antibody (1:100; BA1627, Wuhan Boster Biotechnology Company, Wuhan, Hubei Province, China) or rabbit anti-rat Nrf2 monoclonal antibody(1:150; PB0327, Wuhan Boster Biotechnology Company), as the primary antibody, and then with horseradish peroxidase-conjugated goat anti-rabbit IgG, as the secondary antibody (1:100; BA1055, Wuhan Boster Biotechnology Company).

Techniques: Expressing, Real-time Polymerase Chain Reaction, Comparison

Journal: Neural Regeneration Research

Article Title: Electroacupuncture alleviates cerebral ischemia and reperfusion injury via modulation of the ERK1/2 signaling pathway

doi: 10.4103/1673-5374.187041

Figure Lengend Snippet: Effects of EA on GCS and Nrf2 immunoreactivities in the ischemic cortex. (A) Immunohistochemical staining for GCS and Nrf2 in the cortex in the different groups (× 400) ( n = 5 per group). (B, C) Mean optical densities of GCS and Nrf2-immunoreactive cells. Data are expressed as the mean ± SEM. Paired t -test was used to compare two groups, while analysis of variance followed by Tukey’s multiple comparisons test was used for multiple comparisons. ** P < 0.01, vs . sham (sham-operation) group; ## P < 0.01, vs . MCAO group; †† P < 0.01, vs . EA (MCAO + EA) group. EA: Electroacupuncture; GCS: glutamylcysteine synthetase; Nrf2: nuclear factor erythroid 2-related factor 2; MCAO: middle cerebral artery occlusion; EA plus PD98059: MCAO + EA + PD98059.

Article Snippet: Then, the sections were incubated with rabbit anti-rat GCS monoclonal antibody (1:100; BA1627, Wuhan Boster Biotechnology Company, Wuhan, Hubei Province, China) or rabbit anti-rat Nrf2 monoclonal antibody(1:150; PB0327, Wuhan Boster Biotechnology Company), as the primary antibody, and then with horseradish peroxidase-conjugated goat anti-rabbit IgG, as the secondary antibody (1:100; BA1055, Wuhan Boster Biotechnology Company).

Techniques: Immunohistochemical staining, Staining

Journal: PLOS ONE

Article Title: Chronic intermittent hypoxia aggravated diabetic cardiomyopathy through LKB1/AMPK/Nrf2 signaling pathway

doi: 10.1371/journal.pone.0296792

Figure Lengend Snippet: (A-E) Representative blot images and quantitative analysis of LKB1, AMPK, Nrf2, HO-1. (F-G) Representative blot images and quantitative analysis of Nuclear-Nrf2. (H-I) Representative images of Nuclear-Nrf2 and the quantitative analysis for Nuclear-Nrf2 (scale bar, 100 μm). n = 3. Data are presented as means ± S.E.M. * p < 0.05 and ** p < 0.01 vs. db/m group; Φ p < 0.05 and ΦΦ p < 0.01 vs. db/db group.

Article Snippet: Seal with 5% skim milk powder sealing solution for 2 h, adding primary antibody and incubating overnight at 4°C: Tubulin (1:10000, GTX628802) and Caspase-3(1:1000, #14220) from CST; p-AMPK (1:2000, AP0116) and HO-1(1:1000, A1346) from ABclonal; PI3K (1:1000, AF6241) from Affinity; LKB1 (1:1000, 10746-1-AP), p-LKB1 (1:5000, 80127-1-RR), AMPK (1:500, 10929-2-AP), p-AKT (1:5000, 66444-1-Ig), AKT (1:5000, 60203-2-Ig), GLUT4 (1:3000, 66846-1-Ig) from Proteintech; Bax (1:1000, GB12690) from Seville; Bcl-2 (1:1000, BA0412) and Nrf2 (1:1000, A0674) from BOSTER; Lamin-B1(1:1000, SI17-06) from Huabio.

Techniques:

Journal: PLOS ONE

Article Title: Chronic intermittent hypoxia aggravated diabetic cardiomyopathy through LKB1/AMPK/Nrf2 signaling pathway

doi: 10.1371/journal.pone.0296792

Figure Lengend Snippet: (A) The cell viability of H9C2 cells was treated with HG with 0, 10, 30, and 50mM for 24 and 48 h. (B) The H9C2 cells were treated with IH and HG for 24 and 48 h, and cell viability of H9C2 cells was measured. (C) The cell viability of H9C2 cells treated with IH and HG. n = 6. (D-E) Representative images of mitochondrial membrane potential and quantitative analysis of the JC-1 ratio. n = 4. (F-G) Representative images of ROS and quantitative analysis of ROS. (H-K) Representative blot images and quantitative analysis of LKB1, AMPK, and Nrf2. n = 3. Data are presented as means ± S.E.M. * p < 0.05 and ** p < 0.01 vs. CON group; Φ p < 0.05 and ΦΦ p < 0.01 vs. HG group.

Article Snippet: Seal with 5% skim milk powder sealing solution for 2 h, adding primary antibody and incubating overnight at 4°C: Tubulin (1:10000, GTX628802) and Caspase-3(1:1000, #14220) from CST; p-AMPK (1:2000, AP0116) and HO-1(1:1000, A1346) from ABclonal; PI3K (1:1000, AF6241) from Affinity; LKB1 (1:1000, 10746-1-AP), p-LKB1 (1:5000, 80127-1-RR), AMPK (1:500, 10929-2-AP), p-AKT (1:5000, 66444-1-Ig), AKT (1:5000, 60203-2-Ig), GLUT4 (1:3000, 66846-1-Ig) from Proteintech; Bax (1:1000, GB12690) from Seville; Bcl-2 (1:1000, BA0412) and Nrf2 (1:1000, A0674) from BOSTER; Lamin-B1(1:1000, SI17-06) from Huabio.

Techniques: Membrane

Journal: PLOS ONE

Article Title: Chronic intermittent hypoxia aggravated diabetic cardiomyopathy through LKB1/AMPK/Nrf2 signaling pathway

doi: 10.1371/journal.pone.0296792

Figure Lengend Snippet: (A-B) Representative images of mitochondrial membrane potential and quantitative analysis of the JC-1 ratio. (C-D) Representative images and quantitative analysis of ROS. (E-G) Representative blot images and quantitative analysis of AMPK and Nrf2. n = 3. Data are presented as means ± S.E.M. * p < 0.05 and ** p < 0.01 vs. CON group; Φ p < 0.05 and ΦΦ p < 0.01 vs. IH+HG group.

Article Snippet: Seal with 5% skim milk powder sealing solution for 2 h, adding primary antibody and incubating overnight at 4°C: Tubulin (1:10000, GTX628802) and Caspase-3(1:1000, #14220) from CST; p-AMPK (1:2000, AP0116) and HO-1(1:1000, A1346) from ABclonal; PI3K (1:1000, AF6241) from Affinity; LKB1 (1:1000, 10746-1-AP), p-LKB1 (1:5000, 80127-1-RR), AMPK (1:500, 10929-2-AP), p-AKT (1:5000, 66444-1-Ig), AKT (1:5000, 60203-2-Ig), GLUT4 (1:3000, 66846-1-Ig) from Proteintech; Bax (1:1000, GB12690) from Seville; Bcl-2 (1:1000, BA0412) and Nrf2 (1:1000, A0674) from BOSTER; Lamin-B1(1:1000, SI17-06) from Huabio.

Techniques: Membrane

Journal: Antioxidants

Article Title: Hydrogen Sulfide Donor GYY4137 Rescues NRF2 Activation in Respiratory Syncytial Virus Infection

doi: 10.3390/antiox11071410

Figure Lengend Snippet: H 2 S donor GYY4137 activates and rescues NRF2 in RSV infection. ( a ) Primary human small airway epithelial cells (SAECs) were treated with 1, 3, or 5 mM GYY4137 or its vehicle. Cells were harvested 17 h after treatment and total cell lysates were analyzed by Western blot with anti-NRF2 antibody. The membrane was reprobed with anti-β-actin antibody for loading control. Western blot image is one representative of three independent experiments. The graph shows the densitometric analysis of NRF2 after normalization to β-actin expressed as mean ± SEM. Data were analyzed by one-way ANOVA followed by Tukey’s test (* p < 0.05 vs. CTR); ( b ) SAECs uninfected and infected with RSV were treated with 5 mM GYY4137 (or vehicle). GYY4137 was added 1 h after RSV infection. Cells were harvested 18 h post-infection (hpi) and total cell lysates were analyzed by Western blot with anti-NRF2 antibody. The membrane was reprobed with anti-β-actin antibody for loading control. Western blot image is one representative of three independent experiments. The graph shows the densitometric analysis of NRF2 after normalization to β-actin expressed as mean ± SEM. Data were analyzed by two-way ANOVA followed by Tukey’s test (* p < 0.05 vs. CTR; # p < 0.05 vs. RSV); ( c ) SAECs were infected with RSV followed by treatment with 5 mM GYY4137. Cells were harvested 18 hpi and RSV proteins were detected in total cell lysates by Western blot using anti-RSV antibody. RSV proteins corresponding bands are indicated on the right. The membrane was reprobed with anti-β-actin for loading control. Western blot image is one representative of two independent experiments.

Article Snippet: The NRF2 was immunoprecipitated from the total cell lysates (containing 1 mg of total protein) with 8 μg of anti-NRF2 antibody (PM069, MBL International Corporation, Woburn, MA, USA) and the NRF2 ubiquitination was analyzed by Western blot with anti-ubiquitin antibody (AUB01-HRP, Cytoskeleton, Denver, CO, USA).

Techniques: Infection, Western Blot, Membrane, Control

Journal: Antioxidants

Article Title: Hydrogen Sulfide Donor GYY4137 Rescues NRF2 Activation in Respiratory Syncytial Virus Infection

doi: 10.3390/antiox11071410

Figure Lengend Snippet: H 2 S donor GYY4137 rescues NRF2-dependent gene expression in RSV infection. SAECs uninfected and infected with RSV were treated with 5 mM GYY4137 and harvested 18 hpi to prepare total RNA. SOD1, catalase, NQO1, GCLC, and GCLM gene expression were quantified by RT-qPCR. Graphs show combined data from three independent experiments expressed as mean ± SEM. The results were analyzed by two-way ANOVA followed by Tukey’s test (* p < 0.05 vs. CTR; # p < 0.05 vs. RSV).

Article Snippet: The NRF2 was immunoprecipitated from the total cell lysates (containing 1 mg of total protein) with 8 μg of anti-NRF2 antibody (PM069, MBL International Corporation, Woburn, MA, USA) and the NRF2 ubiquitination was analyzed by Western blot with anti-ubiquitin antibody (AUB01-HRP, Cytoskeleton, Denver, CO, USA).

Techniques: Gene Expression, Infection, Quantitative RT-PCR

Journal: Antioxidants

Article Title: Hydrogen Sulfide Donor GYY4137 Rescues NRF2 Activation in Respiratory Syncytial Virus Infection

doi: 10.3390/antiox11071410

Figure Lengend Snippet: H 2 S donor GYY4137 restores NRF2 ubiquitination and does not affect histone deacetylase (HDAC) activity in RSV infection. ( a ) SAECs uninfected and infected with RSV were treated with 5 mM GYY4137 and harvested 18 hpi. NRF2 was immunoprecipitated from total cell lysates with anti-NRF2 antibody and NRF2 ubiquitination was analyzed by Western blot with anti-ubiquitin antibody. The membrane was stripped and reprobed with anti-NRF2 antibody to determine levels of immunoprecipitated NRF2. A sample of the original pre-immunoprecipitation lysate was also analyzed by Western blot to show levels of NRF2 before immunoprecipitation (input). Western blot images are one representative of three independent experiments. Graph shows densitometric analysis of NRF2 ubiquitination after normalization to immunoprecipitated NRF2 expressed as mean ± SEM. Data were analyzed by two-way ANOVA followed by Tukey’s test (* p < 0.05 vs. CTR; # p < 0.05 vs. RSV); ( b ) SAECs, uninfected and infected with RSV, were treated with 5 mM GYY4137 and harvested 18 hpi. HDAC activity (class I and class II) in nuclear extracts was measured using HDAC Fluorometric Activity Assay Kit (Cayman Chemical). The HDAC activity was normalized by protein concentration. The graph shows combined data from three independent experiments expressed as mean ± SEM. Data were analyzed by two-way ANOVA followed by Tukey’s test (* p < 0.05 vs. CTR).

Article Snippet: The NRF2 was immunoprecipitated from the total cell lysates (containing 1 mg of total protein) with 8 μg of anti-NRF2 antibody (PM069, MBL International Corporation, Woburn, MA, USA) and the NRF2 ubiquitination was analyzed by Western blot with anti-ubiquitin antibody (AUB01-HRP, Cytoskeleton, Denver, CO, USA).

Techniques: Ubiquitin Proteomics, Histone Deacetylase Assay, Activity Assay, Infection, Immunoprecipitation, Western Blot, Membrane, Protein Concentration

Journal: Cell Death & Disease

Article Title: Nrf2 overexpression increases risk of high tumor mutation burden in acute myeloid leukemia by inhibiting MSH2

doi: 10.1038/s41419-020-03331-x

Figure Lengend Snippet: a TMB values of mutation sites in Nrf2 high/low expression group (n = 6). b The percentage of blast cells were detected in Nrf2 high/low AML specimens ( n = 30). c Disease-related gene mutations were shown in AML patients with high/low expression of Nrf2 by whole-exon sequencing ( n = 6). d Studies in the Oncomine database showed higher mRNA expression of Nrf2 in AML patients with FLT3-ITD, NPM1, KRAS positive mutations (n = 526). e Expression levels of Nrf2 protein were detected in AML specimens by western blotting (P: patient, n = 14). f Quantification of Nrf2 expression in AML samples. g mRNA expression of Nrf2 in AML by qRT-PCR ( n = 33). Results are presented as means ± SD; TMB, tumor mutation burden. * p < 0.05, ** p < 0.01.

Article Snippet: Anti-Nrf2 (K106685P) antibody was obtained from Solarbio (Beijing, China).

Techniques: Mutagenesis, Expressing, Sequencing, Western Blot, Quantitative RT-PCR

Journal: Cell Death & Disease

Article Title: Nrf2 overexpression increases risk of high tumor mutation burden in acute myeloid leukemia by inhibiting MSH2

doi: 10.1038/s41419-020-03331-x

Figure Lengend Snippet: a The heatmap of hierarchical clustering showed the differentially expressed genes in the Nrf2 high/low expressed group based on RNAseq analysis ( n = 7). b KEGG pathway analysis showed that Nrf2 expression was inhibited DNA Mismatch repair (MMR) in the AML. The KEGG pathway with P < 0.05 was shown in a bubble plot. c qRT-PCR analysis of the expression of the MMR genes, including MSH2, MLH1, POLD2, RFC4, PMS2, and MSH6 in the Nrf2 high/low expressed group ( n = 33). d Expression levels of MSH2 protein were detected in AML samples by western blotting (n = 9). e Quantification of MSH2 expression in Nrf2-High group and Nrf2-Ligh group. f Representative images of ICC staining of MSH2 in AML (P1 and P6, Nrf2-Low group; P9 and P10, Nrf2-High group), Scale bars: 100 and 50 μm from left to right. Results are presented as means ± SD; * p < 0.05, ** p < 0.01, ns, no significance.

Article Snippet: Anti-Nrf2 (K106685P) antibody was obtained from Solarbio (Beijing, China).

Techniques: Expressing, Quantitative RT-PCR, Western Blot, Staining

Journal: Cell Death & Disease

Article Title: Nrf2 overexpression increases risk of high tumor mutation burden in acute myeloid leukemia by inhibiting MSH2

doi: 10.1038/s41419-020-03331-x

Figure Lengend Snippet: a Nrf2 was overexpressed or silenced in THP-1 and Kasumi-1 cell lines determined by western blot analyses. b The relative gray values were shown in histogram. c Nrf2 was overexpressed or silenced in THP-1 and Kasumi-1 cell lines determined by qRT-PCR analyses. d , e The necrotic cells in different groups were detected after Hoechst 33342 staining (scale bars, 20 µm). f The Nrf2-overexpressing cells were treated with or without Ara-C (2 μM) for 24 h. The Nrf2 and MSH2 protein levels were assessed by western blotting. g The relative gray values were shown in histogram. h The silencing Nrf2 cells were treated with or without Ara-C (2 μM) for 24 h. The Nrf2 and MSH2 protein levels were assessed by western blotting. i The relative gray values were shown in histogram. Data are presented as the mean ± SD of three independent experiments. EV, empty vector. Ara-C, cytarabine. * P < 0.05, ** P < 0.01, ns, no significance.

Article Snippet: Anti-Nrf2 (K106685P) antibody was obtained from Solarbio (Beijing, China).

Techniques: Western Blot, Quantitative RT-PCR, Staining, Plasmid Preparation

Journal: Cell Death & Disease

Article Title: Nrf2 overexpression increases risk of high tumor mutation burden in acute myeloid leukemia by inhibiting MSH2

doi: 10.1038/s41419-020-03331-x

Figure Lengend Snippet: a Representative images of tumor-bearing mice in the indicated cells. b Images of subcutaneous xenografts from mice in the EV1, L-Nrf2, EV1 + Ara-C, and L-Nrf2+Ara-C groups. n = 16. c Tumor weight change curves for subcutaneous xenografts. d Tumor volume growth curves for subcutaneous xenografts. e Survival analysis curves for subcutaneous xenografts. Survival was plotted by using the Kaplan–Meier method. f The expression of Nrf2 and MSH2 was examined in xenograft tumor tissue sections using immunohistochemistry (scale bars: 100 and 50 μm from left to right). * P < 0.05, ** P < 0.01.

Article Snippet: Anti-Nrf2 (K106685P) antibody was obtained from Solarbio (Beijing, China).

Techniques: Expressing, Immunohistochemistry

Journal: Cell Death & Disease

Article Title: Nrf2 overexpression increases risk of high tumor mutation burden in acute myeloid leukemia by inhibiting MSH2

doi: 10.1038/s41419-020-03331-x

Figure Lengend Snippet: a The cells were treated with Ara-C (2 μM) for 24 h. Nrf2-overexpressing and empty vector cells were stained with DCFH-DA to measure intracellular ROS production by flow cytometry. b The percentage of apoptotic cells was demonstrated by flow cytometry in both cell lines following the overexpression of Nrf2. c Nrf2-overexpressing cells were pretreated with or without H 2 O 2 (50 μM). Protein expression levels of Nrf2 and MSH2 were detected by western blotting. d The relative gray values were shown in histogram. e Silencing Nrf2 cells were pretreated with or without NAC (5 mM). Protein expression levels of Nrf2 and MSH2 were detected by western blotting. f The relative gray values were shown in histogram. Data are presented as the mean ± SD of three independent experiments. EV, empty vector. Ara-C, cytarabine. NAC, Nacetylcysteine. * P < 0.05, ** P < 0.01, ns, no significance.

Article Snippet: Anti-Nrf2 (K106685P) antibody was obtained from Solarbio (Beijing, China).

Techniques: Plasmid Preparation, Staining, Flow Cytometry, Over Expression, Expressing, Western Blot

Journal: Cell Death & Disease

Article Title: Nrf2 overexpression increases risk of high tumor mutation burden in acute myeloid leukemia by inhibiting MSH2

doi: 10.1038/s41419-020-03331-x

Figure Lengend Snippet: a Protein-protein interaction network of Nrf2,MSH2 and JUN (GeneMANIA). b After treatment with or without 10 μM SP600125 for 24 h in THP-1 cells, protein expression levels of Nrf2, MSH2, JNK, pJNK, c-Jun and p-c-Jun was evaluated by western blot analysis in the Nrf2-overexpression and EV groups. c The relative gray values were shown in histogram. d After treatment with or without 10 μM SP600125 for 24 h in Kasumi-1 cells, protein expression levels of Nrf2, MSH2, JNK, pJNK, c-Jun, and p-c-Jun was evaluated by western blot analysis in the Nrf2-overexpression and EV groups. e The relative gray values were shown in histogram. Data are presented as the mean ± SD of three independent experiments. * P < 0.05, ** P < 0.01, ns, no significance.

Article Snippet: Anti-Nrf2 (K106685P) antibody was obtained from Solarbio (Beijing, China).

Techniques: Expressing, Western Blot, Over Expression

Journal: Cell Death & Disease

Article Title: Nrf2 overexpression increases risk of high tumor mutation burden in acute myeloid leukemia by inhibiting MSH2

doi: 10.1038/s41419-020-03331-x

Figure Lengend Snippet: Nrf2 reduced cytarabine-induced ROS and positively regulated JNK, activating the phosphorylated c-Jun, leading to inhibition of DNA MMR and finally mutation-dependent chemoresistance.

Article Snippet: Anti-Nrf2 (K106685P) antibody was obtained from Solarbio (Beijing, China).

Techniques: Inhibition, Mutagenesis

Journal: Cell Death & Disease

Article Title: Nrf2 overexpression increases risk of high tumor mutation burden in acute myeloid leukemia by inhibiting MSH2

doi: 10.1038/s41419-020-03331-x

Figure Lengend Snippet: The characteristics of the primers used for qRT-PCR.

Article Snippet: Anti-Nrf2 (K106685P) antibody was obtained from Solarbio (Beijing, China).

Techniques: Sequencing